Healthcare
Sandoz Group AG(SDZNY)
Live Price
Offline$84.32
-1.30% today
1Y Change
+57.84%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $34.60B
- Revenue Growth
- -14.9%
- EPS Growth
- 0.0%
- Dividend Yield
- 1.3%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sandoz Group AG (SDZNY) is a Healthcare stock with a market cap of $34.60B and listed on OTC. The stock last traded around $84.32 and up 57.8% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -14.9%, EPS growth of 0.0%, a dividend yield of 1.3%. What stands out right now is revenue -14.9%, EPS 0.0%, free cash flow +1250.0% with operating margin 14.6% and ROIC 7.8%. The dividend is present but secondary, with a yield around 1.3%. Valuation already assumes a fairly strong business story at P/E 37.5 and price/sales 3.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SDZNY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-14.9% vs +7.6% peer median
Operating Margin
Below sector median
+14.6% vs +19.4% peer median
P/E
Near sector median
37.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Mar 3, 2026 with revenue ahead of estimates by +94.0%.
The operating picture looks softer than before
Revenue is at -14.9% and EPS is at 0.0%, with operating margin around 14.6%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.3%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 3, 2026 | โ | +1.0% | -4.2% | -7.4% |
2025 Aug 7, 2025 | โ | -5.9% | -6.1% | -1.6% |
2025 Mar 5, 2025 | โ | -1.4% | +2.3% | +9.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SDZNY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SDZNY Max Drawdown
-19.09%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SDZNY and SPY.
Company Overview
Sandoz Group AG
Other OTC
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
- Leadership
- Richard Saynor
- IPO Date
- Oct 4, 2023
- Employees
- 22.0k
- Street Address
- Suurstoffi 14
- Mailing
- Rotkreuz, 6343
- Region
- Rotkreuz, CH
- Reporting Currency
- USD
- Investor Line
- 41 61 324 11 11
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 37.5
- EV/EBITDA
- 23.6
- Price/Sales
- 3.1
- Price/Book
- 3.7
Growth
- Revenue
- -14.9%
- EPS
- 0.0%
- Free Cash Flow
- +1250.0%
Profitability
- Gross Margin
- 47.2%
- Operating Margin
- 14.6%
- Net Margin
- 8.2%
- ROE
- 10.1%
- ROIC
- 7.8%
Balance Sheet
- Debt/Equity
- 0.61
- Current Ratio
- 1.18
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.